Literature DB >> 1658151

Tumor necrosis factor-alpha regulates expression of receptors for formyl-methionyl-leucyl-phenylalanine, leukotriene B4, and platelet-activating factor. Dissociation from priming in human polymorphonuclear neutrophils.

J T O'Flaherty1, A G Rossi, J F Redman, D P Jacobson.   

Abstract

TNF-alpha enhances polymorphonuclear responses to many stimuli, including chemotactic peptide FMLP. It also promotes expression of FMLP receptors and thus may prime polymorphonuclear neutrophils to this and other agonists by up-regulating signal recognition molecules. However, we find that the cytokine's actions on FMLP receptors lagged priming of FMLP-induced degranulation. Moreover, TNF-alpha enhanced degranulation responses to leukotriene B4 and platelet-activating factor but paradoxically down-regulated leukotriene B4 receptors and only transiently up-regulated platelet-activating factor receptors. Hence, TNF-alpha has pleiotropic effects on receptor expression; these effects diverge from priming; and a large part of the primed state must reflect enhancement of post-receptor events.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1658151

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Systemic response of peripheral blood leukocytes and their phagocytic activity during acute myocardial infarction.

Authors:  P M Djurdjevic; N N Arsenijevic; D D Baskic; A L Djukic; S Popovic; G Samardzic
Journal:  Exp Clin Cardiol       Date:  2001

2.  Platelet-activating factor receptor mRNA is localized in eosinophils and epithelial cells in rat small intestine: regulation by dexamethasone and gut flora.

Authors:  H Wang; X Tan; H Chang; W Huang; F Gonzalez-Crussi; W Hsueh
Journal:  Immunology       Date:  1999-07       Impact factor: 7.397

Review 3.  Adaptive and maladaptive mechanisms of cellular priming.

Authors:  D R Meldrum; J C Cleveland; E E Moore; D A Partrick; A Banerjee; A H Harken
Journal:  Ann Surg       Date:  1997-11       Impact factor: 12.969

4.  Differential priming effects of proinflammatory cytokines on human neutrophil oxidative burst in response to bacterial N-formyl peptides.

Authors:  C Elbim; S Bailly; S Chollet-Martin; J Hakim; M A Gougerot-Pocidalo
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

5.  Interleukin-18 primes the oxidative burst of neutrophils in response to formyl-peptides: role of cytochrome b558 translocation and N-formyl peptide receptor endocytosis.

Authors:  Carole Elbim; Cécile Guichard; Pham M C Dang; Michèle Fay; Eric Pedruzzi; Hélène Demur; Cécile Pouzet; Jamel El Benna; Marie-Anne Gougerot-Pocidalo
Journal:  Clin Diagn Lab Immunol       Date:  2005-03

6.  Interleukin-8 primes human neutrophils for enhanced superoxide anion production.

Authors:  A Wozniak; W H Betts; G A Murphy; M Rokicinski
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

7.  Subcellular localization and translocation of the receptor for N-formylmethionyl-leucyl-phenylalanine in human neutrophils.

Authors:  H Sengeløv; F Boulay; L Kjeldsen; N Borregaard
Journal:  Biochem J       Date:  1994-04-15       Impact factor: 3.857

8.  Regulation of platelet-activating-factor receptors and the desensitization response in polymorphonuclear neutrophils.

Authors:  J T O'Flaherty; D P Jacobson; J F Redman
Journal:  Biochem J       Date:  1992-11-15       Impact factor: 3.857

9.  Characterization of inositol hexakisphosphate (InsP6)-mediated priming in human neutrophils: lack of extracellular [3H]-InsP6 receptors.

Authors:  E Kitchen; A M Condliffe; A G Rossi; C Haslett; E R Chilvers
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

10.  Priming of the oxidative burst in human neutrophils by physiological agonists or cytochalasin B results from the recruitment of previously non-responsive cells.

Authors:  R H Daniels; M A Elmore; M E Hill; Y Shimizu; J M Lackie; M J Finnen
Journal:  Immunology       Date:  1994-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.